Clinical Trials Resource Center

Knee Injuries

August 1, 2011

Histogenics released results from a phase II trial of their NeoCart Autologous Cartilage Tissue Implant (ACTI). This randomized, controlled study enrolled 30 subjects with knee cartilage injury who received the NeoCart implant or underwent microfracture (MF) repair surgery. The results showed ACTI treatment using NeoCart led to statistically significant improvements in knee and general health outcomes scores by six months, at the primary endpoint of twelve months, and were then sustained for at least two years. NeoCart had a higher proportion of therapeutic responders in comparison to MF at one and two years.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.